Clinical trial
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With…
NCT00138216 · Children's Oncology Group, Other · Completed
Key facts
| NCT number | NCT00138216 |
|---|---|
| Title | Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors |
| Official title | A Phase I Study of Temozolomide, Oral Irinotecan, and Vincristine for Children With Refractory Solid Tumors |
| Lead sponsor | Children's Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | irinotecan hydrochloride, temozolomide, vincristine sulfate |
| Enrollment | 42 |
| Start date | Oct 1, 2005 |
| Primary completion | Jun 1, 2009 |
| Completion | Jan 1, 2011 |
| First posted | Aug 30, 2005 |
| Last update posted | Oct 2, 2023 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: